Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-07-30
2009-10-06
Rawlings, Stephen L (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S387300, C530S387700, C530S388850
Reexamination Certificate
active
07598353
ABSTRACT:
Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof.
REFERENCES:
patent: 3940475 (1976-02-01), Gross
patent: 4289747 (1981-09-01), Chu
patent: 4376110 (1983-03-01), David et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5508717 (1996-04-01), Miller
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5780279 (1998-07-01), Matthews et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 6040136 (2000-03-01), Garrard et al.
patent: 6338851 (2002-01-01), Gorczynski
patent: 6652858 (2003-11-01), Gorczynski et al.
patent: 6749854 (2004-06-01), Gorczynski et al.
patent: 6955811 (2005-10-01), Gorczynski et al.
patent: 6984625 (2006-01-01), Gorczynski
patent: 7238352 (2007-07-01), Gorczynski et al.
patent: 2002/0031515 (2002-03-01), Caligiuri et al.
patent: 2002/0168364 (2002-11-01), Gorczynski et al.
patent: 2002/0192215 (2002-12-01), Hoek et al.
patent: 2003/0017491 (2003-01-01), Shi et al.
patent: 2004/0018972 (2004-01-01), Gorczynski et al.
patent: 2004/0054145 (2004-03-01), Gorczynski
patent: 2004/0175692 (2004-09-01), Bowdish et al.
patent: 2004/0198661 (2004-10-01), Bowdish et al.
patent: 2005/0048069 (2005-03-01), Gorczynski et al.
patent: 2005/0107214 (2005-05-01), Koenig
patent: 2005/0129690 (2005-06-01), Bowdish et al.
patent: 2005/0169870 (2005-08-01), Truitt et al.
patent: WO-8403508 (1984-09-01), None
patent: WO-8503508 (1985-08-01), None
patent: WO-9215679 (1992-09-01), None
patent: WO-9428027 (1994-12-01), None
patent: WO-9518825 (1995-07-01), None
patent: WO-9627011 (1996-09-01), None
patent: WO-9638557 (1996-12-01), None
patent: WO-9708320 (1997-03-01), None
patent: WO-9721450 (1997-06-01), None
patent: WO-8806630 (1998-09-01), None
patent: WO-9924565 (1999-05-01), None
patent: WO-02011762 (2002-02-01), None
patent: WO-02042332 (2002-05-01), None
patent: WO-02/059280 (2002-08-01), None
patent: WO-02095030 (2002-11-01), None
patent: WO-03025202 (2003-03-01), None
patent: WO-2004078937 (2004-09-01), None
Alizadeh et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, 403:503-511(2000).
Auchincloss et al. “Strategies to Induce Tolerance,” Transplantation Immunology, Bach and Auchincloss, Eds., Wiley-Liss, New York, Chapter 11, pp. 211-218 (1995).
Bach, “Immunosuppressive therapy of autoimmune diseases,” Immunology Today, 14(6)322-326 1993.
Banerjee, D., et al., “Blocking CD200-CD200 receptor axis augments NOS-2 expression and aggravates experimental autoimmune uveoretinitis in Lewis rats,” Ocular Immunology and Inflammation, 12(2):115-125 (2004).
Barclay and Ward, “Purification and Chemical Characterisation of Membrane Glycoproteins From Rat Thymocytes and Brain, Recognised by Monoclonal Antibody MRC OX2,” European J. Biochemistry, 129:447-458(1982).
Barclay et al.,“CD200 and membrane protein interactions in the control of myeloid cells,” Trends in Immunology, 23(6):2002.
Barclay, A.N., “Different reticular elements in rat lymphoid tissue identified by localization of Ia, Thy-1 and MRC OX 2 antigens,” Immunology, 44:727-736 (1981).
Barclay, A.N., et al., “Neuronal/Lymphoid Membrane Glycoprotein MRC OX-2 is a Member of the Immunoglobulin Superfamily with a Light-Chain-Like Structure,” Biochem. Soc. Symp., 51:149-157 (1985).
Blazer, B.R., et al., “CD28/B7 Interactions Are Required for Sustaining the Graft-Versus-Leukemia Effect of Delayed Post-Bone Marrow Transplantation Splenocyte Infusion in Murine Recipients of Myeloid or Lymphoid Leukemia Cells,” J. Immunol., 159:3460-3473 (1997).
Bohen, S.P., “Variation in gene expression patterns in follicular lymphoma and the response to rituximab,” PNAS, 100(4):1926-1930(2003).
Boon, Thierry., “Toward a Genetic Analysis of Tumor Rejection Antigens,” Advances in Cancer Res., 58:177-210(1992).
Borriello et al., “MRC OX-2 Defines a Novel T Cell Costimulatory Pathway,” J. Immunol., 158:4549-4554(1997).
Borriello, F., et al., “Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX - 2 membrane glycoprotein,” Mammalian Genome, 9(2):114-118 (1998).
Broderick et al., “Constitutive Retinal CD200 Expression Regulates Resident Microglia and Activin State of Inflammatory Cells During Experimental Autoimmune Uveoretinitis,” Am. J. Of Pathology, 161(5):1669-1677(2002).
Bodey et al. “Human Cancer Detection and Immunotherapy with Conjugated and Non-Conjugated Monoclonal Antibodies” Anticancer Research 16: 661-674 (1996).
Bukovsky, A., et al., “Association of lymphoid cell markers with rat ascitic malignant cells,” IRCS Med. Sci., 11:866-867 (1983).
Bukovsky, A., et al., “Association of some cell surface antigens of lymphoid cells and cell surface differentiation antigens with early rat pregnancy,” Immunology, 52:631-640 (1984).
Bukovsky, A., et al., “The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and follopian tube,” Immunology , 48:587-596 (1983).
Bukovsky, A., et al., “The ovarian follicle as a model for the cell-mediated control of tissue growth,” Cell Tissue Res., 236:717-724(1984).
Caldes et al., “Humanization of the anti-CD 18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen,” Mol. Immunol. 39:941-952 (2003).
Chaouat and Clark, FAS/FAS Ligand Interaction at the Placental Interface is not Required for the Success of Allogeneic Pregnancy in Anti-Paternal MHC Preimmunized Mice, Presented at the 6th Congress of the Adria-Alps Soc. of Immunol. of Reprod., (2000) / Amer. J. of Reprod. Immunol., 45:108-115(2001).
Chen, D., et al., “Discrete Monoclonal Antibodies Define Functionally Important Epitopes in the CD200 Molecule Responsible for lmmunosupression Function,” Transplantation, 79:282- 288 2005.
Chen, D., et al., “Synthetic peptides from the N-terminal regionsl of CD200 and CD200R1 modulate immunosupressive and anti-inflammatory effects of CD200-CD200R1 interaction,” International Immunology, 17(3):289-296 (2005).
Chen, Z., et al., “Cloning and characterization of the murine homologue of the rat/human MRC OX - 2 gene,” Database Medline, Biochemica et Biophysica Acta, 1362(1):6-10 (1997).
Cherwinski, H.M., et al., “The CD200 Receptor Is a Novel and Potent Regulator of Murine and Human Mast Cell Function,” J. Immunol., 174:1348-1356 (2005).
Chien et al., “Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: proposal of a structural mechanism,” Proc. Natl. Acad. Sci. USA 86:5532-5536 (1989).
Chitnis et al., “The Role of CD200 in Immune-Modulation and Neural Protection in EAE,” Abstract, 12th International Congress of Immunology and 4th Annual Conference of FOCIS, Montreal, Jul. 21, 2004.
Chitnis, T., et al., “Elevated Neuronal Expression of CD200 ProtectsWldSMice from Inflammation-Mediated Neurodegeneration,” American Journal of Pathology, 170(5):1695- 1712 (2007).
Clark et al., “Fg12 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered b OX-2,” Mol. Human Reprod., 7:185-194(2001) .
Cla
Bowdish Katherine S.
Kretz-Rommel Anke
Maruyama Toshiaki
McWhirter John
Alexion Pharmaceuticals, Inc.
Duffy Brad
Rawlings Stephen L
Ropes & Gray LLP
LandOfFree
Polypeptides and antibodies derived from chronic lymphocytic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides and antibodies derived from chronic lymphocytic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides and antibodies derived from chronic lymphocytic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142498